Mohamad A Raad1, Nour H Chams1, Ala I Sharara2. 1. School of Medicine, American University of Beirut, Beirut, Lebanon. 2. Division of Gastroenterology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Abstract
BACKGROUND: Crohn's disease and ulcerative colitis are chronic inflammatory disorders associated with a dysregulated adaptive and innate immune response to gut commensals in genetically susceptible individuals. The pathogenesis of inflammatory bowel disease is complex, and the disease is characterized by significant phenotypic and genotypic heterogeneity. SUMMARY: The introduction of anti-TNF biologics has resulted in improved clinical outcomes in patients with severe and moderately severe disease, but the current treatment paradigm continues to depend on systemic immunosuppression (steroids and immunomodulators) and surgical intervention in a significant number of patients, underscoring a significant unmet need. More recently, a number of genetic and immunologic abnormalities have been unraveled including aberrant intestinal mucosal defense function, abnormal intestinal permeability, dysregulated bacterial antigen processing by macrophages and presentation to T cells, cellular immune regulation and signaling, cytokine production, and leukocyte trafficking. KEY MESSAGES: Understanding these molecular mechanisms and effector pathways presents an opportunity for the development of new and improved targeted therapies.
BACKGROUND: Crohn's disease and ulcerative colitis are chronic inflammatory disorders associated with a dysregulated adaptive and innate immune response to gut commensals in genetically susceptible individuals. The pathogenesis of inflammatory bowel disease is complex, and the disease is characterized by significant phenotypic and genotypic heterogeneity. SUMMARY: The introduction of anti-TNF biologics has resulted in improved clinical outcomes in patients with severe and moderately severe disease, but the current treatment paradigm continues to depend on systemic immunosuppression (steroids and immunomodulators) and surgical intervention in a significant number of patients, underscoring a significant unmet need. More recently, a number of genetic and immunologic abnormalities have been unraveled including aberrant intestinal mucosal defense function, abnormal intestinal permeability, dysregulated bacterial antigen processing by macrophages and presentation to T cells, cellular immune regulation and signaling, cytokine production, and leukocyte trafficking. KEY MESSAGES: Understanding these molecular mechanisms and effector pathways presents an opportunity for the development of new and improved targeted therapies.
Authors: Holm H Uhlig; Brent S McKenzie; Sophie Hue; Claire Thompson; Barbara Joyce-Shaikh; Renata Stepankova; Nicolas Robinson; Sofia Buonocore; Helena Tlaskalova-Hogenova; Daniel J Cua; Fiona Powrie Journal: Immunity Date: 2006-08 Impact factor: 31.745
Authors: Julián Panés; Chinyu Su; Andrew G Bushmakin; Joseph C Cappelleri; Carla Mamolo; Paul Healey Journal: BMC Gastroenterol Date: 2015-02-05 Impact factor: 3.067
Authors: Ashley J Snider; Wahida H Ali; Jonathan A Sticca; Nicolas Coant; Amr M Ghaleb; Toshihiko Kawamori; Vincent W Yang; Yusuf A Hannun; Lina M Obeid Journal: PLoS One Date: 2014-12-02 Impact factor: 3.240
Authors: Craig A Murphy; Claire L Langrish; Yi Chen; Wendy Blumenschein; Terrill McClanahan; Robert A Kastelein; Jonathon D Sedgwick; Daniel J Cua Journal: J Exp Med Date: 2003-12-08 Impact factor: 14.307
Authors: Barun Das; John Rabalais; Philip Kozan; Tina Lu; Nassim Durali; Kevin Okamoto; Matthew D McGeough; Beom Jae Lee; Kim E Barrett; Ronald Marchelletta; Mamata Sivagnanam Journal: PLoS One Date: 2022-07-08 Impact factor: 3.752